Home

Past Trials

E-mail Print PDF

 

TIS: TENECTAPLASE IN STROKE TRIAL

Phase IIb, randomised, multicentre, single blinded (outcomes blind to treatment arm) trial of intravenous tenecteplase (TNK) versus alteplase (tPA) in acute ischaemic stroke patients. Three arms (tenecteplase 0.1 mg/kg, tenecteplase 0.25 mg/kg, alteplase 0.9 mg/kg) with 1:1:1 randomisation. Patients randomised to treatment within 1.2 and CTP based infarct core <1/3 middle cerebral artery territory. The primary hypothesis being tested in this trial is that ischaemic stroke patients treated with TNK will have greater reperfusion (measured at 24 hours) than tPA. Secondary outcomes include early clinical improvement and parenchymal haematoma.

A total of 75 participants were recruited
 

 

2008

PROFESS

To compare the efficacy and safety of Aggrenox®(25 mg aspirin/200 mg extended-release dipyridamole) with Clopidogrel (Plavix®), and to compare Micardis® (telmisartan) with placebo in in the presence of background anti-hypertensive treatment in the prevention of recurrent stroke.

 

RE-LY                  

Randomized Evaluation of Long term therapy comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel group, non- inferiority trial.

 

ROCKET        

A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation.

 

STICH II

To establish whether a policy of earlier surgical evacuation of hematomas in selected patients with spontaneous lobar ICH will improve outcome compared to a policy of initial conservative treatment.

 

VITATOPS

To determine whether lowering plasma homocysteine concentrations by the administration of vitamin supplements (folic acid 2 mg, B6 25 mg, B12 500 μg) will reduce the incidence of vascular sequelae following recent stroke or transient ischemic attacks (TIA).

 

2007

TRA-P2

To evaluate the effect of SCH 530348, administered for a minimum of 1 year, with respect to the incidence of atherothrombotic events (composite of cardiovascular (CV) death, myocardial infarction (MI), stroke, or urgent coronary revascularization) in subjects with documented atherosclerotic disease receiving standard therapy.

2006

CHARISMA

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management & Avoidance)

A phase III, Multicentre, Multinational, Randomised, Parrallel Group, Double-Blind Trial of chlopidogrol versus Placebo in High-Risk Patients aged over 45 Years and Older, at Risk of Atherothrombotic Events, and who are recieveing background therapy including low-dose ASA.

PREVAIL

Prevention of Venous Thrombo Embolism after Acute Ischemic Stroke with Low Molecular Weight Heparin)To demonstrate superiority of enoxaparin compared to unfractionated heparin (UFH) in the prevention of Venous Thromboembolism (VTE) following acute ischemic stroke.              

 

Last Updated ( Thursday, 25 August 2011 15:07 )  

Members Login


ASTN Latest news

Top Views